Assessment of therapeutic potential of arsenic trioxide in the management of human hepatocellular carcinoma

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter E. Dugo
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors E. Dugo, C. Yedjou, J. Stevens, P. Tchounwou
  • Jackson State University, Jackson, Mississippi, USA, /

Abstract

Arsenic trioxide (ATO or Trisenox) has been used for the treatment of acute promyelocytic leukemia. However, its potential effects on liver cancer are not known. In the present study, we hypothesized that ATO may also exert a bioactivity against hepatocellular cancer, and its mechanisms of action may be mediated through oxidative stress, genotoxicity, apoptosis, as well as changes in transcription and signaling molecules.